Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

New EMA product specific guidance (PSG) [BE/BA News]

posted by SMA – Europe, 2024-01-16 10:51 (489 d 18:07 ago) – Posting: # 23828
Views: 3,258
(edited on 2024-01-16 11:07)

Dear all

EMA has published two new PSGs:

Azacitidine powder for suspension for injection 25 mg/ml product-specific bioequivalence guidance (here)
Paliperidone palmitate depot suspension for injection (every 3 months) 175, 263, 350 and 525 mg product-specific bioequivalence guidance (here)

Consultations open until 2024-04-30

Complete thread:

New EMA product specific guidance (PSG)SMA 2024-01-16 09:51 [BE/BA News]
- New EMA product specific guidance (PSG) dshah 2024-01-17 10:12

Admin contact
23,424 posts in 4,927 threads, 1,683 registered users;
88 visitors (0 registered, 88 guests [including 10 identified bots]).
Forum time: 05:58 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery. Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz